Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aldesleukin and Pembrolizumab in Advanced Renal Cell Carcinoma
NCT03260504Phase 1Terminated
- Sponsor
- University of Washington
- Start
- Aug 2018
- Primary completion
- Jul 2022
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aldesleukin in renal cell carcinoma (RCC), sponsored by University of Washington. Primary endpoint: Number of Adverse Events at 36 weeks. Started Aug 2018; status: terminated.
02
Drugs
aldesleukin
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03260504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03260504.